Regulation of Gene Expression by PML
PML 对基因表达的调控
基本信息
- 批准号:7118005
- 负责人:
- 金额:$ 29.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-30 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The promyelocytic leukemia PML gene is consistently disrupted by the nonrandom chromosomal translocation t(15; 17) in acute promyelocytic leukemia. PML is a protein with multiple functions involves in regulation of apoptosis, cell cycle progression, gene expression, genome stability, and cellular senescence. How PML involves in such diverse multiple regulatory functions remains unknown. When fused downstream of the GAL4-DNA binding domain, PML acts as a transcriptional repressor by recruiting histone deacetylases. PML also represses transcription by interacting with different transcription factors including Sp 1, Nur77, and NF-kappaB and disrupt their binding to the DNA target sites. PML activates fos-mediated AP-1 transactivation. PML also mediates transactivation by recruiting coactivator CBP has been reported by several groups, strongly supporting a role of PML in transcription activation. PML interacts with p53, forms a PML/p53/CBP complex and upregulates p53 mediated transcription. The objectives of this proposal are to understand the mechanisms of gene expression regulated by PML. Based on the results accomplished in the preliminary studies, our main hypothesis is that PML regulates transcription by (1) interaction and sequestration of transcription factors; (2) recruits CBP/HDACs to the target promoters to achieve transcriptional activation and repression. The following three specific aims will be pursued to support the hypothesis: 1. We will study the mechanism and functional significance of transcriptional repression by PML. Our hypothesis predicts that PML interacts and sequesters transcription factors and limiting their accessibility to the DNA binding sites. We will test the hypothesis by CHIP assay, double color immunofluorescence staining, co-purification of PML and its associated proteins in the nuclear matrix, and to study how PML regulates the availability of Spl during G1/S cell cycle transition. 2. We will study the functional significance of different PML isoforms in mediating expression of target genes. We hypothesize that alternative splicing of the primary PML transcript produces various isoforms with different C-terminals regulating different target genes. We will study the transcriptional regulatory functions of different PML isoforms; study the expression pattern, cellular distribution. 3. We will identify and characterize the PML target genes mediated through HDACs and CBP. Our hypothesis predicts that PML recruits corepressors HDACs and coactivator CBP to the target promoters and represses/activates transcription. We will identify PML target genes by construction and screening of a chromatin immunoprecipitated DNA library, identify the PML target genes by the genome-wide location technology, and to characterize the PML target genes. Finally we will investigate whether these PML target genes are deregulated in acute promyelocytic leukemia.
描述(由申请人提供):急性早幼粒细胞白血病中的非随机染色体易位t(15; 17)持续破坏早幼粒细胞白血病PML基因。PML是一种具有多种功能的蛋白质,涉及细胞凋亡、细胞周期进程、基因表达、基因组稳定性和细胞衰老的调节。PML如何参与如此多样的多重调节功能仍不清楚。当融合在GAL 4-DNA结合域下游时,PML通过募集组蛋白脱乙酰酶而充当转录抑制因子。PML还通过与不同的转录因子(包括Sp 1、Nur 77和NF-κ B)相互作用抑制转录,并破坏它们与DNA靶位点的结合。PML激活fos介导的AP-1反式激活。PML还通过募集共激活因子CBP介导转录激活,几个研究小组已报告,强烈支持PML在转录激活中的作用。PML与p53相互作用,形成PML/p53/CBP复合物并上调p53介导的转录。该提案的目的是了解PML调控基因表达的机制。基于初步研究的结果,我们的主要假设是PML通过(1)转录因子的相互作用和隔离来调节转录;(2)将CBP/HDAC募集到靶启动子以实现转录激活和抑制。以下三个具体目标将被追求,以支持这一假设:1。我们将研究PML抑制转录的机制和功能意义。我们的假设预测,PML相互作用和隔离转录因子,并限制其访问的DNA结合位点。我们将通过CHIP法、免疫荧光双染色、共纯化PML及其相关蛋白来验证这一假设,并研究PML在G1/S细胞周期转换过程中对Spl的调节作用。2.我们将研究不同PML亚型在介导靶基因表达中的功能意义。我们假设,选择性剪接的主要PML转录产生不同的C-末端调节不同的靶基因的各种亚型。我们将研究不同PML亚型的转录调控功能,研究其表达模式、细胞分布。3.我们将鉴定和表征通过HDAC和CBP介导的PML靶基因。我们的假设预测,PML招募辅抑制因子HDAC和辅激活因子CBP的目标启动子和抑制/激活转录。我们将通过构建和筛选染色质免疫沉淀DNA文库来鉴定PML靶基因,通过全基因组定位技术来鉴定PML靶基因,并对PML靶基因进行表征。最后,我们将研究这些PML靶基因在急性早幼粒细胞白血病中是否失调。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KUN-SANG CHANG其他文献
KUN-SANG CHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KUN-SANG CHANG', 18)}}的其他基金
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子病理学
- 批准号:
6192152 - 财政年份:1992
- 资助金额:
$ 29.53万 - 项目类别:
A Role for PML in Genome Stability and DNA Damage Response
PML 在基因组稳定性和 DNA 损伤反应中的作用
- 批准号:
8215849 - 财政年份:1992
- 资助金额:
$ 29.53万 - 项目类别:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子病理学
- 批准号:
2330801 - 财政年份:1992
- 资助金额:
$ 29.53万 - 项目类别:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子病理学
- 批准号:
2871764 - 财政年份:1992
- 资助金额:
$ 29.53万 - 项目类别:
A Role for PML in Genome Stability and DNA Damage Response
PML 在基因组稳定性和 DNA 损伤反应中的作用
- 批准号:
7373528 - 财政年份:1992
- 资助金额:
$ 29.53万 - 项目类别:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子病理学
- 批准号:
3200074 - 财政年份:1992
- 资助金额:
$ 29.53万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 29.53万 - 项目类别:
Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 29.53万 - 项目类别:














{{item.name}}会员




